According to the East Asia Pharmaceutical announcement, the cumulative daily closing price increase deviation value of the company's stock reached 20% during the three consecutive trading days of September 8, September 9, and September 10, 2026, which is an abnormal fluctuation in stock trading. After self-inspection, it was verified by the controlling shareholders and actual controllers Chi Zhengming and Chi Cheng that as of the date of disclosure of the announcement, there were no important matters that should have been disclosed but not disclosed, and the directors, supervisors, and controlling shareholders and actual controllers had not traded the company's shares during the period of change. The company's net loss for the first half year of 2026 was 118 million yuan, with continuous losses since 2024. Investors are kindly requested to pay attention to investment risks.

According to the East Asia Pharmaceutical announcement, the cumulative daily closing price increase deviation value of the company's stock reached 20% during the three consecutive trading days of September 8, September 9, and September 10, 2026, which is an abnormal fluctuation in stock trading. After self-inspection, it was verified by the controlling shareholders and actual controllers Chi Zhengming and Chi Cheng that as of the date of disclosure of the announcement, there were no important matters that should have been disclosed but not disclosed, and the directors, supervisors, and controlling shareholders and actual controllers had not traded the company's shares during the period of change. The company's net loss for the first half year of 2026 was 118 million yuan, with continuous losses since 2024. Investors are kindly requested to pay attention to investment risks.